Entity family

Browse diseases

Named diseases, disorders, syndromes, injuries, and health conditions. Examples include epilepsy, diabetes, stroke.

3articles mentioning diseases

7disease mentions

1distinct diseases extracted

0%of mentions human-reviewed

Active filtersEntity: mNSCLC ×

mNSCLC

This disease is selected. Its supporting articles are shown below.

Articles mentioning mNSCLC

3 articles · page 1 of 1

508 Biomarker analysis of coformulation of vibostolimab with pembrolizumab (vibo/pembro) with or without docetaxel for metastatic non-small-cell lung cancer (mNSCLC) after chemotherapy and immunotherapy

jitc · abstract · 2025-11-04 · 3 matching annotations

98.0%

mNSCLC docetaxel pembrolizumab vibo/pembro vibostolimab platinum chemotherapy

…tibody pembrolizumab (vibo/pembro) with or without docetaxel in mNSCLC previously treated with anti-PD-(L)1 therapy and platinum chemo…

509 High tumor burden as a negative predictive tool of outcome to mono-immunotherapy in stage IV NSCLC

jitc · abstract · 2025-11-04 · 3 matching annotations

91.9%

mNSCLC metastatic non-small-cell carcinoma Careggi University Hospital ICI

…TB as a negative predictor of response to mono-immunotherapy in mNSCLC with a PD-L1 ≥ 50%. The identification of this subgroup of pati…

Atezolizumab and bevacizumab, with or without radiotherapy, versus docetaxel in patients with metastatic non-small cell lung cancer previously treated with a checkpoint inhibitor and chemotherapy: results from the randomized, phase Ib/II MORPHEUS-Lung study

jitc · abstract · 2025-08-04 · 1 matching annotations

87.7%

mNSCLC metastatic non-small cell lung cancer (mNSCLC)docetaxel atezolizumab bevacizumab

…e checkpoint inhibitor (CPI)-exposed patients with non-squamous mNSCLC and without targetable gene mutations.Methods MORPHEUS-Lung enr…